In the wake of an FBI search of his office over a possibly criminal deal with other drugmakers, Bristol-Myers Squibb CEO Peter Dolan maintains his aplomb. The criminal inquiry is into a deal reached by Bristol and marketing partner Sanofi-Aventis with Apotex to settle its patent suit over the Plavix blood-thinner, now rejected by 56 attorneys general.

Full Story:

Related Summaries